Page 31 - MemoriaBBN-Eng

www.ciber-bbn.es

b) Therapeutic nanoconjugates and drug delivery systems:

This line will concentrate on the development of new pharmacological therapies

based on the intelligent design of guided nanoconjugates. It contemplates both
the development of pharmacological delivery systems optimized to traverse the

blood-brain barrier and the delivery especially of enzymes, proteins or gene inhi-

bition strategies by means of siRNA. Priority will be given to obtaining therapeutic
nanoconjugates in prevalent clinical areas and in rare diseases.

The pharmacological reformulation of drugs already existing in clinical practice

will not be a priority, nor will technological development not associated with a
relevant clinical need. The line must assure that toxicological and therapeutic

activity data is obtained in all the newly designed nanoconjugates. The basic ob-

jective is to obtain suitable proofs of concept.

The development of therapeutic nanoconjugates and of localized and controlled
delivery systems for these nanoconjugates will allow guiding the treatment to the

area of action, in the attempt to achieve perfect control of the therapy, thereby

preventing the action of the drug or therapeutic particle, in areas that may entail
a potential risk for the patient.

The groups is focusing on applied research with a translational research approach

aimed at the therapeutic application of delivery systems for drugs and nanopar-
ticles that have therapeutic activity, or as diagnosis agents, or agents for inter-

nalizing/distributing drugs. This approach also aims to apply active molecules

or nanoconjugates in scaffolds or other mechanisms for specific applications in
tissue engineering and implants.

In addition, the group is investigating the development of therapeutically active

molecules, the development of nanoconjugates, compression of active devices ú

and their internalization in tissue and integration in the organism.

A total of 21 intramural projects have been conducted in the Nanomedicine Pro-
Intramural
gramme in 2012-2013:
í
projects of the óó

programme

Use of non-invasive techniques for controlling
NANOXEN
nervous functions in animal models.

Coordinating PI: Fausto Sanz / Participating PIs: R. Eritja, JC.
Izpisa, external clinical groups.

Nano-engineering inclusion bodies as new
NAINBO
biomaterials for cell proliferation.

Coordinating PI: Jaume Veciana. / Participating PIs: A. Villaverde,
N. Vilaboa.
13
20
T
Development of nanoparticles as vehicles for the OR
NANOCOMETS
treatment of metastatic colorectal cancer.
P
RE
Coordinating PI: Ramn Mangues / Participating PIs: J. Pavía, A. L
Villaverde, R. Martnez, F. Albericio, S. Schwartz.
A
NU
Targeted thearpy to improve the treatment of N
NANOSTEMNESS
A
advanced breast cancer.
N /
Coordinating PI: Sim Schwartz. / Participating PIs: J. Veciana, A. B
-B
Villaverde, external groups.
R
BE
CI

31